Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 73 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Isis Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Isis Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Isis Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Isis Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Isis Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Isis Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Isis Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Isis Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Isis Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Isis Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Isis Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Isis Pharmaceuticals, Inc. Snapshot 7
Isis Pharmaceuticals, Inc. Overview 7
Key Information 7
Key Facts 7
Isis Pharmaceuticals, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Isis Pharmaceuticals, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Isis Pharmaceuticals, Inc. - Pipeline Products Glance 18
Isis Pharmaceuticals, Inc. - Late Stage Pipeline Products 18
Phase III Products/Combination Treatment Modalities 18
Isis Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Isis Pharmaceuticals, Inc. - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Discovery Products/Combination Treatment Modalities 22
Isis Pharmaceuticals, Inc. - Drug Profiles 23
ISIS-TTRRx 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ISIS-APOCIIIRx 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ISIS-CRPRx 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ISIS-EIF4ERx 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ISIS-FXIRx 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ISIS-GCCRRx 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ISIS-GCGRRx 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ISIS-PTP1BRx 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ISIS-SMNRx 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ISIS-ANGPTL3 Rx 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ISIS-APOARx 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ISIS-FGFR4Rx 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ISIS-HBVRx 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ISIS-SOD1Rx 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CideB Antisense Oligonucleotide 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ISIS-AATRx 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ISIS-DGAT2Rx 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ISIS-DMPKRx 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ISIS-FVIIRx 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ISIS-GSK4 Rx 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ISIS-HTTRx 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ISIS-PKKRx 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Antisense Oligonucleotides for Neurology 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Isis Pharmaceuticals, Inc. - Pipeline Analysis 48
Isis Pharmaceuticals, Inc. - Pipeline Products by Target 48
Isis Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 50
Isis Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 51
Isis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 52
Isis Pharmaceuticals, Inc. - Recent Pipeline Updates 54
Isis Pharmaceuticals, Inc. - Dormant Projects 67
Isis Pharmaceuticals, Inc. - Discontinued Pipeline Products 68
Discontinued Pipeline Product Profiles 68
ISIS-104838 68
ISIS-113715 68
ISIS-14803 68
ISIS-2503 68
ISIS-5132 69
ISIS-EIF4ERx 69
Isis Pharmaceuticals, Inc. - Company Statement 70
Isis Pharmaceuticals, Inc. - Locations And Subsidiaries 71
Head Office 71
Other Locations & Subsidiaries 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Isis Pharmaceuticals, Inc., Key Information 7
Isis Pharmaceuticals, Inc., Key Facts 7
Isis Pharmaceuticals, Inc. - Pipeline by Indication, 2014 9
Isis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 11
Isis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 12
Isis Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 13
Isis Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 14
Isis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 15
Isis Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 16
Isis Pharmaceuticals, Inc. - Phase III, 2014 18
Isis Pharmaceuticals, Inc. - Phase II, 2014 19
Isis Pharmaceuticals, Inc. - Phase I, 2014 20
Isis Pharmaceuticals, Inc. - Preclinical, 2014 21
Isis Pharmaceuticals, Inc. - Discovery, 2014 22
Isis Pharmaceuticals, Inc. - Pipeline by Target, 2014 49
Isis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 50
Isis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 51
Isis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 53
Isis Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 54
Isis Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 67
Isis Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 68
Isis Pharmaceuticals, Inc., Subsidiaries 71